SCHEMBL2575343

SCHEMBL2575343

CC(C)(C)c1ccc(C(O)c2ccccc2OCc2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
RAB9A P51151 1/20 0.43
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
RXRA P19793 3/20 0.42
RXRB P28702 3/20 0.42
RXRG P48443 2/20 0.42
SGMS2 Q8NHU3 7/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
NR4A2 P43354 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
NR4A1 P22736 1/20 0.40
NR4A3 Q92570 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2579113 0.86 PPIA (0.46) DRD2DRD1RXRARXRBRXRG
SCHEMBL477534 0.85 DRD2 (0.55) LIPEL3MBTL1DRD2DRD1MAPT
SCHEMBL2577406 0.85 LIPE (0.46) LIPEL3MBTL1DRD2DRD1MAPT
SCHEMBL2578523 0.85 SGMS2 (0.54) LIPEL3MBTL1DRD2DRD1MAPT
SCHEMBL1539311 0.83 LIPE (0.45) LIPEL3MBTL1DRD2DRD1MAPT
SCHEMBL31041187 0.83 SLC6A9 (0.47) LIPEL3MBTL1RAB9ADRD2DRD1
SCHEMBL2575133 0.82 DRD2 (0.46) LIPEL3MBTL1RAB9ADRD2DRD1
SCHEMBL2577640 0.82 SGMS2 (0.54) LIPEL3MBTL1RAB9ADRD2DRD1
SCHEMBL2577600 0.81 LIPE (0.43) LIPEL3MBTL1DRD2DRD1MAPT
SCHEMBL4003187 0.81 MAPK1 (0.49) LIPEL3MBTL1DRD2DRD1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
CN-101010276-B Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same CHUGAI PHARMACEUTICAL CO LTD 2011-01-12 CN disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
CN-101010276-A Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same CHUGAI PHARMACEUTICAL CO LTD (JP) 2007-08-01 CN disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 LIPE 320/4885L3MBTL1 1828/4885RAB9A 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.